• banner_1.jpg
  • banner_2.jpg
  • banner_3.jpg
  • banner_4.jpg
  • banner_5.jpg
  • banner_6.jpg
  • innovation_group_photo.jpg

Current Development Programs


Herpes Simplex Virus Type 2 (HSV-2)

HSV-2 is the major causative agent of genital herpes. This disease does not just cause discomfort to infected individuals but can have serious health implications for babies born to infected women and is believed to aid the transmission of human immunodeficiency virus (HIV). Current HSV treatment involves the use of antiviral drugs which can reduce, but not eliminate, outbreaks and shedding and therefore does not prevent spread of the disease. Coridon is now conducting a Phase I clinical study in Brisbane to trial its HSV-2 DNA vaccine in healthy volunteers, who have never had a cold sore or herpes infection.


Epstein Barr Virus (EBV)

EBV is the causative agent of infectious mononucleosis (IM; glandular fever) in young adults and has been linked with Burkitt’s lymphoma, nasopharyngeal carcinoma (NPC), Hodgkin’s disease, non-Hodgkin’s lymphoma and lymphoproliferative diseases in the immunosupressed. Coridon is undertaking research and development of a prophylactic/therapeutic vaccine for EBV: prophylactic for IM and post-transplant lymphoproliferative disease and therapeutic for recurrent infection as a cause of NPC (in Asia) and lymphoma (in Africa).


Human Papilloma Virus (HPV)

HPV is one of the most common sexually transmitted diseases in the world and, as well as cervical cancer, is associated with a variety of anogenital cancers and head and neck cancer. Cervical cancer is the second largest cause of cancer deaths in women worldwide. Coridon is undertaking research and development of a therapeutic vaccine to combat existing HPV infection and to prevent and treat cervical and other HPV-associated cancers. An effective therapeutic vaccine has enormous potential in both the treatment of patients and reduction in deaths from HPV-associated cancers.


Coridon’s optimisation technology could potentially be applied to the development of DNA vaccines for a range of infectious diseases and cancers.  Furthermore, as the technology should stimulate not only a strong antibody response but also a robust cellular immune response, it is particularly suited to the development of therapeutic vaccines.